Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

Astrid Friebe* (First author), Martin Horn, Folkhart Schmidt, Gesa Janssen, Monika-H Schmid-Wendtner, Matthias Volkenandt, Axel Hauschild, Charlie H Goldsmith, Martin Schaefer

*Corresponding author for this work

    Research output: Contribution to journalOriginal Articlepeer-review

    39 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)466-473
    JournalPSYCHOSOMATICS
    Volume51
    Issue number6
    DOIs
    Publication statusPublished - 2010

    Keywords

    • HEPATITIS-C
    • HIGH-RISK
    • PEGYLATED INTERFERON-ALPHA-2A
    • CUTANEOUS MELANOMA
    • THERAPY
    • PAROXETINE
    • CANCER
    • TRIAL

    Cite this